SUBSCRIBE
SUBSCRIBE

Phase 1

Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
AstraZeneca PLC’s Immunotherapy Lung Cancer Combo Treatment Sees Breakthrough in Early Stage Trial
February 8, 2016
 · 
3 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Lab Criticized as ‘Slow to React’ in Bial’s Fatal Drug Trial
February 5, 2016
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
With Almost $200 Million in the Bank, WAVE Life Sciences Plans Six Clinical Programs in Three Years
January 29, 2016
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Akashi Halts DMD Clinical Trial, Third Company to Recently Have Problems With DMD Drug Trials
January 26, 2016
 · 
3 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Questions Remain as to What Caused the Bial Trial Tragedy in France
January 19, 2016
 · 
2 min read
Pfizer and Allergan Execs Emphasize Joint Company’s Pipeline, Hint Job Cuts Will Be Minimal
Drug Development
Biogen’s Promising Pipeline Underscores CEO’s High-Risk Strategy
January 18, 2016
 · 
4 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Drugmaker Unnamed as Botched Trial in France Leaves One Patient Brain Dead and Five Hospitalized
January 15, 2016
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Business
Booming Moderna Eyes Six Human Trials in 2016, Inks Deals with AstraZeneca PLC, Merck & Co. and Signed Huge Lease in Cambridge for R&D Growth
January 12, 2016
 · 
3 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Drug Development
RestorGenex and Diffusion Pharma Merge to Form Wholly-Owned Oncology Subsidiary
December 28, 2015
 · 
2 min read
Drug Development
KaloBios Fires Martin Shkreli, UC Davis Suspends Leukemia Trial Due to Shkreli
December 21, 2015
 · 
3 min read
Load More
PRESS RELEASES
Press Releases
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026
February 25, 2026
 · 
11 min read
Press Releases
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC
February 25, 2026
 · 
5 min read
Press Releases
Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)
February 25, 2026
 · 
8 min read
Press Releases
FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update
February 25, 2026
 · 
7 min read
Press Releases
Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease
February 25, 2026
 · 
6 min read
Press Releases
Vico Therapeutics Announces Patient Dosing in Twice-Annual Regimen of VO659 in Phase 1/2 Trial in Huntington’s Disease, Spinocerebellar Ataxia Type 3 and Type 1
February 24, 2026
 · 
3 min read
Press Releases
Cartography Biosciences Doses First Patient in Phase 1 Trial of CBI-1214, a Highly Specific T-Cell Engager for the Treatment of Colorectal Cancer
February 24, 2026
 · 
4 min read
Press Releases
AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics’ Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01)
February 24, 2026
 · 
4 min read
Press Releases
Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01)
February 24, 2026
 · 
4 min read
Press Releases
Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)
February 24, 2026
 · 
10 min read
Press Releases
AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor
February 24, 2026
 · 
6 min read
Press Releases
Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
February 24, 2026
 · 
11 min read
Press Releases
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052
February 24, 2026
 · 
5 min read
Press Releases
Centauri Therapeutics Extends Series A to £30M With £6M Investment From AMR Action Fund to Support Progression of Lead Clinical Candidate
February 24, 2026
 · 
3 min read
Press Releases
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
February 24, 2026
 · 
20 min read
Press Releases
Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
February 24, 2026
 · 
10 min read
Press Releases
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026
February 24, 2026
 · 
9 min read
Press Releases
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates
February 24, 2026
 · 
11 min read
Press Releases
Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026
February 23, 2026
 · 
7 min read
Press Releases
Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference
February 23, 2026
 · 
6 min read
Load More